公开(公告)号：US11185575B2

公开(公告)日：2021-11-30

申请号：US16567048

申请日：2019-09-11

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Alexandra Nathalie Kopic ,  Werner Hollriegl ,  Barbara Plaimauer ,  Hanspeter Rottensteiner ,  Eva-Maria Muchitsch

IPC: A61K38/48 ,  C12N9/64 ,  A61K9/00 ,  A61K9/19

Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.

公开(公告)号：US11779635B2

公开(公告)日：2023-10-10

申请号：US17525759

申请日：2021-11-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Alexandra Nathalie Kopic ,  Werner Hoellriegl ,  Barbara Plaimauer ,  Hanspeter Rottensteiner ,  Eva-Maria Muchitsch

IPC: A61K38/48 ,  C12N9/64 ,  A61K9/00 ,  A61K9/19

CPC classification number: A61K38/4886 ,  A61K9/0019 ,  A61K9/19 ,  C12N9/6489 ,  C12Y304/24087

Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.